Abstract
IntroductionEdaravon, being a potential neuro-protective and neuro-tropic agent, was suggested for use in traumatic brain injury. During its use in 94 patients, a higher incidence of hypoalbuminemia was noted in a subset of trauma patients with severe brain injury. Material and method94 patients were evaluated after administration of edaravon for the outcome of therapy in terms of Glasgow outcome score and the incidence of hypoalbuminemia. This was compared with 33 non-parallel patients of head injury who were not administered the medicine. ResultThe incidence of hypoalbuminemia and associated morbidity was found to be significant to reconsider the use of this medicine for severe traumatic brain injury. The outcome of patients treated with the medicine when compared with a non-parallel control group suggested that there was no significant benefit in administering edaravon in traumatic brain injury. ConclusionIn spite of its limitations, this study emphasizes the need for further randomized placebo controlled studies before edaravon is considered for use in neuro-trauma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
